share_log

Adagene to Present at the Leerink Partners Global Biopharma Conference 2024

Adagene to Present at the Leerink Partners Global Biopharma Conference 2024

Adagene 將出席 2024 年 Leerink Partners 全球生物製藥大會
天演藥業 ·  02/27 00:00

SAN DIEGO and SUZHOU, China, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its participation in the Leerink Partners Global Biopharma Conference 2024, taking place March 11-13 in Miami, Florida.

中國聖地亞哥和蘇州,2024年2月27日(GLOBE NEWSWIRE)——致力於改變新型抗體療法發現和開發的公司Adagene Inc.(“Adagene”)(納斯達克股票代碼:ADAG)今天宣佈參加3月11日至13日在佛羅里達州邁阿密舉行的2024年Leerink Partners全球生物製藥大會。

Adagene's Chairman, Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will provide an update on its masked, anti-CTLA-4 SAFEbody ADG126, including key milestones for 2024. Company management will also host investor meetings.

Adagene董事長、首席執行官兼研發總裁Peter Luo博士將介紹其蒙面抗CTLA-4 SafeBody的最新情況 ADG126,包括 2024 年的關鍵里程碑。公司管理層還將主持投資者會議。

Leerink Partners Global Biopharma Conference 2024

Leerink Partners 2024 年全球生物製藥大會

  • Date:
Tuesday, March 12
  • Presentation Time:
1:40 PM (Eastern Time)
  • Location:
The Fontainebleau Miami
  • 日期:
3 月 12 日,星期二
  • 演講時間:
下午 1:40(東部時間)
  • 地點:
邁阿密楓丹白露酒店

A live webcast of the presentation will also be accessible in the Investors section of the company's website at https://www.adagene.com. A webcast replay will be available for at least 30 days.

演示文稿的網絡直播也可以在以下網址觀看 投資者 公司網站的部分位於 https://www.adagene.com。網絡直播重播將持續至少 30 天。

About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody, SAFEbody, and POWERbody technologies, Adagene's highly differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.

關於 Adagene
Adagene Inc.(納斯達克股票代碼:ADAG)是一家平台驅動的臨床階段生物技術公司,致力於改變基於抗體的新型癌症免疫療法的發現和開發。Adagene結合了計算生物學和人工智能,設計了滿足未滿足的患者需求的新型抗體。由其專有的動態精密庫 (DPL) 平台提供支持,該平台由 NeoBody、SafeBody 組成和PowerBody技術,Adagene高度差異化的產品線以新穎的免疫療法項目爲特色。Adagene已與信譽良好的全球合作伙伴建立了戰略合作關係,這些合作伙伴以多種方法利用其技術,處於科學前沿。

For more information, please visit: https://investor.adagene.com. Follow Adagene on WeChat, LinkedIn and Twitter.

欲了解更多信息,請訪問: https://investor.adagene.com。繼續關注 Adagene 微信領英推特

SAFEbody is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.

安全身體 是美國、中國、澳大利亞、日本、新加坡和歐盟的註冊商標。

Investor & Media Contact:
Ami Knoefler
Adagene
650-739-9952
ir@adagene.com

投資者和媒體聯繫人:
阿米·諾夫勒
Adagene
650-739-9952
ir@adagene.com

Primary Logo

Source: Adagene Inc.

資料來源:Adagene Inc.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論